K. Moss

发表

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation

A. Waterson, A. King, B. Heidrich, 2009 .

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.

P. Sabbatini, J. Eksterowicz, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

A Selective and Oral Small Molecule Inhibitor of VEGFR-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability

G. Mcmahon, Neela Patel, K. Leahy, 2003 .

Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).

A. Gilmartin, K. Hayakawa, H. Kawasaki, 2011, ACS medicinal chemistry letters.

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Francesca Zappacosta, David Sutton, R. Annan, 2011, Clinical Cancer Research.

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.

Alastair J. King, Alex G. Waterson, A. Waterson, 2013, ACS medicinal chemistry letters.

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

A. King, J. Erhardt, D. Uehling, 2013, PloS one.

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

Ramona N Plant, J. Adams, M. A. Hardwicke, 2009, Molecular Cancer Therapeutics.

Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.

J. Cherrington, D. Mendel, Guangmin Li, 2003, Molecular cancer therapeutics.

SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

J. Cherrington, J. Christensen, D. Mendel, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans

J. Cherrington, D. Mendel, A. Laird, 2003, Journal of Pharmacology and Experimental Therapeutics.

JPET #52530 Hair Depigmentation is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans

J. Cherrington, A. Laird, K. Moss, 2003 .

Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.

Brent M. Sanders, H. Alsaid, Rakesh Kumar, 2013, Cancer research.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

O. Potapova, J. Cherrington, Angela Barone, 2006, Molecular Cancer Therapeutics.

A Selective and Oral Small Molecule Inhibitor of Vascular Epithelial Growth Factor Receptor (VEGFR)-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability

A. Howlett, G. Mcmahon, Qingling Zhang, 2003, Journal of Pharmacology and Experimental Therapeutics.

Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo.

Thomas O. Toole, J. Mulé, T. O’Toole, 1996, Blood.

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

R. Annan, A. Gilmartin, E. Minthorn, 2011, Clinical Cancer Research.